Viridian Therapeutics completes routine 2026 Annual Meeting with all proposals approved

Filed June 3, 2026 · Period ending June 2, 2026 · ~1 min read

Key Changes

• low

  Stockholders elected two Class II directors (Tomas Kiselak and Jennifer K. Moses) to serve three-year terms through 2029, with Moses receiving 99.5% support and Kiselak receiving 83% support.

  Item 5.07 verify on EDGAR →
• low

  Executive compensation received 96% stockholder approval in advisory say-on-pay vote, with 83.5 million votes in favor versus 3.1 million against.

  Item 5.07 verify on EDGAR →
• low

  Board adopted annual frequency for future say-on-pay votes following stockholder preference, meaning executive compensation will face advisory vote each year.

  Item 5.07 verify on EDGAR →